IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET)
Background Few new drugs have been developed for chronic pain. Drug development is challenged by uncertainty about whether the drug engages the human target sufficiently to have a meaningful pharmacodynamic effect. IMI2-PainCare-BioPain-RCT1 is one of four similarly designed studies that aim to link...
Saved in:
| Published in | Current controlled trials in cardiovascular medicine Vol. 23; no. 1; pp. 163 - 20 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
19.02.2022
BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1745-6215 1745-6215 |
| DOI | 10.1186/s13063-022-06087-1 |
Cover
| Abstract | Background
Few new drugs have been developed for chronic pain. Drug development is challenged by uncertainty about whether the drug engages the human target sufficiently to have a meaningful pharmacodynamic effect. IMI2-PainCare-BioPain-RCT1 is one of four similarly designed studies that aim to link different functional biomarkers of drug effects on the nociceptive system that could serve to accelerate the future development of analgesics. This study focusses on biomarkers derived from nerve excitability testing (NET) using threshold tracking of the peripheral nervous system.
Methods
This is a multisite single-dose, subject and assessor-blind, randomized, placebo-controlled, 4-period, 4-way crossover, pharmacodynamic (PD), and pharmacokinetic (PK) study in healthy subjects. Biomarkers derived from NET of large sensory and motor fibers and small sensory fibers using perception threshold tracking will be obtained before and three times after administration of three medications known to act on the nociceptive system (lacosamide, pregabalin, tapentadol) and placebo, given as a single oral dose with at least 1 week apart. Motor and sensory NET will be assessed on the right wrist in a non-sensitized normal condition while perception threshold tracking will be performed bilaterally on both non-sensitized and sensitized forearm skin. Cutaneous high-frequency electrical stimulation is used to induce hyperalgesia. Blood samples will be taken for pharmacokinetic purposes and pain ratings as well as predictive psychological traits will be collected. A sequentially rejective multiple testing approach will be used with overall alpha error of the primary analysis split across the two primary outcomes: strength-duration time constant (SDTC; a measure of passive membrane properties and nodal persistent Na
+
conductance) of large sensory fibers and SDTC of large motor fibers comparing lacosamide and placebo. The key secondary endpoint is the SDTC measured in small sensory fibers. Remaining treatment arm effects on key NET outcomes and PK modelling are other prespecified secondary or exploratory analyses.
Discussion
Measurements of NET using threshold tracking protocols are sensitive to membrane potential at the site of stimulation. Sets of useful indices of axonal excitability collectively may provide insights into the mechanisms responsible for membrane polarization, ion channel function, and activity of ionic pumps during the process of impulse conduction. IMI2-PainCare-BioPain-RCT1 hypothesizes that NET can serve as biomarkers of target engagement of analgesic drugs in this compartment of the nociceptive system for future Phase 1 clinical trials. Phase 2 and 3 clinical trials could also benefit from these tools for patient stratification.
Trial registration
This trial was registered 25/06/2019 in EudraCT (2019-000942-36). |
|---|---|
| AbstractList | Abstract Background Few new drugs have been developed for chronic pain. Drug development is challenged by uncertainty about whether the drug engages the human target sufficiently to have a meaningful pharmacodynamic effect. IMI2-PainCare-BioPain-RCT1 is one of four similarly designed studies that aim to link different functional biomarkers of drug effects on the nociceptive system that could serve to accelerate the future development of analgesics. This study focusses on biomarkers derived from nerve excitability testing (NET) using threshold tracking of the peripheral nervous system. Methods This is a multisite single-dose, subject and assessor-blind, randomized, placebo-controlled, 4-period, 4-way crossover, pharmacodynamic (PD), and pharmacokinetic (PK) study in healthy subjects. Biomarkers derived from NET of large sensory and motor fibers and small sensory fibers using perception threshold tracking will be obtained before and three times after administration of three medications known to act on the nociceptive system (lacosamide, pregabalin, tapentadol) and placebo, given as a single oral dose with at least 1 week apart. Motor and sensory NET will be assessed on the right wrist in a non-sensitized normal condition while perception threshold tracking will be performed bilaterally on both non-sensitized and sensitized forearm skin. Cutaneous high-frequency electrical stimulation is used to induce hyperalgesia. Blood samples will be taken for pharmacokinetic purposes and pain ratings as well as predictive psychological traits will be collected. A sequentially rejective multiple testing approach will be used with overall alpha error of the primary analysis split across the two primary outcomes: strength-duration time constant (SDTC; a measure of passive membrane properties and nodal persistent Na+ conductance) of large sensory fibers and SDTC of large motor fibers comparing lacosamide and placebo. The key secondary endpoint is the SDTC measured in small sensory fibers. Remaining treatment arm effects on key NET outcomes and PK modelling are other prespecified secondary or exploratory analyses. Discussion Measurements of NET using threshold tracking protocols are sensitive to membrane potential at the site of stimulation. Sets of useful indices of axonal excitability collectively may provide insights into the mechanisms responsible for membrane polarization, ion channel function, and activity of ionic pumps during the process of impulse conduction. IMI2-PainCare-BioPain-RCT1 hypothesizes that NET can serve as biomarkers of target engagement of analgesic drugs in this compartment of the nociceptive system for future Phase 1 clinical trials. Phase 2 and 3 clinical trials could also benefit from these tools for patient stratification. Trial registration This trial was registered 25/06/2019 in EudraCT ( 2019-000942-36 ). Background Few new drugs have been developed for chronic pain. Drug development is challenged by uncertainty about whether the drug engages the human target sufficiently to have a meaningful pharmacodynamic effect. IMI2-PainCare-BioPain-RCT1 is one of four similarly designed studies that aim to link different functional biomarkers of drug effects on the nociceptive system that could serve to accelerate the future development of analgesics. This study focusses on biomarkers derived from nerve excitability testing (NET) using threshold tracking of the peripheral nervous system. Methods This is a multisite single-dose, subject and assessor-blind, randomized, placebo-controlled, 4-period, 4-way crossover, pharmacodynamic (PD), and pharmacokinetic (PK) study in healthy subjects. Biomarkers derived from NET of large sensory and motor fibers and small sensory fibers using perception threshold tracking will be obtained before and three times after administration of three medications known to act on the nociceptive system (lacosamide, pregabalin, tapentadol) and placebo, given as a single oral dose with at least 1 week apart. Motor and sensory NET will be assessed on the right wrist in a non-sensitized normal condition while perception threshold tracking will be performed bilaterally on both non-sensitized and sensitized forearm skin. Cutaneous high-frequency electrical stimulation is used to induce hyperalgesia. Blood samples will be taken for pharmacokinetic purposes and pain ratings as well as predictive psychological traits will be collected. A sequentially rejective multiple testing approach will be used with overall alpha error of the primary analysis split across the two primary outcomes: strength-duration time constant (SDTC; a measure of passive membrane properties and nodal persistent Na + conductance) of large sensory fibers and SDTC of large motor fibers comparing lacosamide and placebo. The key secondary endpoint is the SDTC measured in small sensory fibers. Remaining treatment arm effects on key NET outcomes and PK modelling are other prespecified secondary or exploratory analyses. Discussion Measurements of NET using threshold tracking protocols are sensitive to membrane potential at the site of stimulation. Sets of useful indices of axonal excitability collectively may provide insights into the mechanisms responsible for membrane polarization, ion channel function, and activity of ionic pumps during the process of impulse conduction. IMI2-PainCare-BioPain-RCT1 hypothesizes that NET can serve as biomarkers of target engagement of analgesic drugs in this compartment of the nociceptive system for future Phase 1 clinical trials. Phase 2 and 3 clinical trials could also benefit from these tools for patient stratification. Trial registration This trial was registered 25/06/2019 in EudraCT (2019-000942-36). BackgroundFew new drugs have been developed for chronic pain. Drug development is challenged by uncertainty about whether the drug engages the human target sufficiently to have a meaningful pharmacodynamic effect. IMI2-PainCare-BioPain-RCT1 is one of four similarly designed studies that aim to link different functional biomarkers of drug effects on the nociceptive system that could serve to accelerate the future development of analgesics. This study focusses on biomarkers derived from nerve excitability testing (NET) using threshold tracking of the peripheral nervous system.MethodsThis is a multisite single-dose, subject and assessor-blind, randomized, placebo-controlled, 4-period, 4-way crossover, pharmacodynamic (PD), and pharmacokinetic (PK) study in healthy subjects. Biomarkers derived from NET of large sensory and motor fibers and small sensory fibers using perception threshold tracking will be obtained before and three times after administration of three medications known to act on the nociceptive system (lacosamide, pregabalin, tapentadol) and placebo, given as a single oral dose with at least 1 week apart. Motor and sensory NET will be assessed on the right wrist in a non-sensitized normal condition while perception threshold tracking will be performed bilaterally on both non-sensitized and sensitized forearm skin. Cutaneous high-frequency electrical stimulation is used to induce hyperalgesia. Blood samples will be taken for pharmacokinetic purposes and pain ratings as well as predictive psychological traits will be collected. A sequentially rejective multiple testing approach will be used with overall alpha error of the primary analysis split across the two primary outcomes: strength-duration time constant (SDTC; a measure of passive membrane properties and nodal persistent Na+ conductance) of large sensory fibers and SDTC of large motor fibers comparing lacosamide and placebo. The key secondary endpoint is the SDTC measured in small sensory fibers. Remaining treatment arm effects on key NET outcomes and PK modelling are other prespecified secondary or exploratory analyses.DiscussionMeasurements of NET using threshold tracking protocols are sensitive to membrane potential at the site of stimulation. Sets of useful indices of axonal excitability collectively may provide insights into the mechanisms responsible for membrane polarization, ion channel function, and activity of ionic pumps during the process of impulse conduction. IMI2-PainCare-BioPain-RCT1 hypothesizes that NET can serve as biomarkers of target engagement of analgesic drugs in this compartment of the nociceptive system for future Phase 1 clinical trials. Phase 2 and 3 clinical trials could also benefit from these tools for patient stratification.Trial registrationThis trial was registered 25/06/2019 in EudraCT (2019-000942-36). Few new drugs have been developed for chronic pain. Drug development is challenged by uncertainty about whether the drug engages the human target sufficiently to have a meaningful pharmacodynamic effect. IMI2-PainCare-BioPain-RCT1 is one of four similarly designed studies that aim to link different functional biomarkers of drug effects on the nociceptive system that could serve to accelerate the future development of analgesics. This study focusses on biomarkers derived from nerve excitability testing (NET) using threshold tracking of the peripheral nervous system. This is a multisite single-dose, subject and assessor-blind, randomized, placebo-controlled, 4-period, 4-way crossover, pharmacodynamic (PD), and pharmacokinetic (PK) study in healthy subjects. Biomarkers derived from NET of large sensory and motor fibers and small sensory fibers using perception threshold tracking will be obtained before and three times after administration of three medications known to act on the nociceptive system (lacosamide, pregabalin, tapentadol) and placebo, given as a single oral dose with at least 1 week apart. Motor and sensory NET will be assessed on the right wrist in a non-sensitized normal condition while perception threshold tracking will be performed bilaterally on both non-sensitized and sensitized forearm skin. Cutaneous high-frequency electrical stimulation is used to induce hyperalgesia. Blood samples will be taken for pharmacokinetic purposes and pain ratings as well as predictive psychological traits will be collected. A sequentially rejective multiple testing approach will be used with overall alpha error of the primary analysis split across the two primary outcomes: strength-duration time constant (SDTC; a measure of passive membrane properties and nodal persistent Na conductance) of large sensory fibers and SDTC of large motor fibers comparing lacosamide and placebo. The key secondary endpoint is the SDTC measured in small sensory fibers. Remaining treatment arm effects on key NET outcomes and PK modelling are other prespecified secondary or exploratory analyses. Measurements of NET using threshold tracking protocols are sensitive to membrane potential at the site of stimulation. Sets of useful indices of axonal excitability collectively may provide insights into the mechanisms responsible for membrane polarization, ion channel function, and activity of ionic pumps during the process of impulse conduction. IMI2-PainCare-BioPain-RCT1 hypothesizes that NET can serve as biomarkers of target engagement of analgesic drugs in this compartment of the nociceptive system for future Phase 1 clinical trials. Phase 2 and 3 clinical trials could also benefit from these tools for patient stratification. This trial was registered 25/06/2019 in EudraCT ( 2019-000942-36 ). Few new drugs have been developed for chronic pain. Drug development is challenged by uncertainty about whether the drug engages the human target sufficiently to have a meaningful pharmacodynamic effect. IMI2-PainCare-BioPain-RCT1 is one of four similarly designed studies that aim to link different functional biomarkers of drug effects on the nociceptive system that could serve to accelerate the future development of analgesics. This study focusses on biomarkers derived from nerve excitability testing (NET) using threshold tracking of the peripheral nervous system.BACKGROUNDFew new drugs have been developed for chronic pain. Drug development is challenged by uncertainty about whether the drug engages the human target sufficiently to have a meaningful pharmacodynamic effect. IMI2-PainCare-BioPain-RCT1 is one of four similarly designed studies that aim to link different functional biomarkers of drug effects on the nociceptive system that could serve to accelerate the future development of analgesics. This study focusses on biomarkers derived from nerve excitability testing (NET) using threshold tracking of the peripheral nervous system.This is a multisite single-dose, subject and assessor-blind, randomized, placebo-controlled, 4-period, 4-way crossover, pharmacodynamic (PD), and pharmacokinetic (PK) study in healthy subjects. Biomarkers derived from NET of large sensory and motor fibers and small sensory fibers using perception threshold tracking will be obtained before and three times after administration of three medications known to act on the nociceptive system (lacosamide, pregabalin, tapentadol) and placebo, given as a single oral dose with at least 1 week apart. Motor and sensory NET will be assessed on the right wrist in a non-sensitized normal condition while perception threshold tracking will be performed bilaterally on both non-sensitized and sensitized forearm skin. Cutaneous high-frequency electrical stimulation is used to induce hyperalgesia. Blood samples will be taken for pharmacokinetic purposes and pain ratings as well as predictive psychological traits will be collected. A sequentially rejective multiple testing approach will be used with overall alpha error of the primary analysis split across the two primary outcomes: strength-duration time constant (SDTC; a measure of passive membrane properties and nodal persistent Na+ conductance) of large sensory fibers and SDTC of large motor fibers comparing lacosamide and placebo. The key secondary endpoint is the SDTC measured in small sensory fibers. Remaining treatment arm effects on key NET outcomes and PK modelling are other prespecified secondary or exploratory analyses.METHODSThis is a multisite single-dose, subject and assessor-blind, randomized, placebo-controlled, 4-period, 4-way crossover, pharmacodynamic (PD), and pharmacokinetic (PK) study in healthy subjects. Biomarkers derived from NET of large sensory and motor fibers and small sensory fibers using perception threshold tracking will be obtained before and three times after administration of three medications known to act on the nociceptive system (lacosamide, pregabalin, tapentadol) and placebo, given as a single oral dose with at least 1 week apart. Motor and sensory NET will be assessed on the right wrist in a non-sensitized normal condition while perception threshold tracking will be performed bilaterally on both non-sensitized and sensitized forearm skin. Cutaneous high-frequency electrical stimulation is used to induce hyperalgesia. Blood samples will be taken for pharmacokinetic purposes and pain ratings as well as predictive psychological traits will be collected. A sequentially rejective multiple testing approach will be used with overall alpha error of the primary analysis split across the two primary outcomes: strength-duration time constant (SDTC; a measure of passive membrane properties and nodal persistent Na+ conductance) of large sensory fibers and SDTC of large motor fibers comparing lacosamide and placebo. The key secondary endpoint is the SDTC measured in small sensory fibers. Remaining treatment arm effects on key NET outcomes and PK modelling are other prespecified secondary or exploratory analyses.Measurements of NET using threshold tracking protocols are sensitive to membrane potential at the site of stimulation. Sets of useful indices of axonal excitability collectively may provide insights into the mechanisms responsible for membrane polarization, ion channel function, and activity of ionic pumps during the process of impulse conduction. IMI2-PainCare-BioPain-RCT1 hypothesizes that NET can serve as biomarkers of target engagement of analgesic drugs in this compartment of the nociceptive system for future Phase 1 clinical trials. Phase 2 and 3 clinical trials could also benefit from these tools for patient stratification.DISCUSSIONMeasurements of NET using threshold tracking protocols are sensitive to membrane potential at the site of stimulation. Sets of useful indices of axonal excitability collectively may provide insights into the mechanisms responsible for membrane polarization, ion channel function, and activity of ionic pumps during the process of impulse conduction. IMI2-PainCare-BioPain-RCT1 hypothesizes that NET can serve as biomarkers of target engagement of analgesic drugs in this compartment of the nociceptive system for future Phase 1 clinical trials. Phase 2 and 3 clinical trials could also benefit from these tools for patient stratification.This trial was registered 25/06/2019 in EudraCT ( 2019-000942-36 ).TRIAL REGISTRATIONThis trial was registered 25/06/2019 in EudraCT ( 2019-000942-36 ). |
| ArticleNumber | 163 |
| Author | Stouffs, Alexandre Caspani, Ombretta Kostenko, Anna V. Pia, Hossein Chapman, Sonya C. Van Niel, Johannes Treede, Rolf-Detlef Fardo, Francesca Vincent, Katy Tankisi, Hatice Troconiz, Iñaki F. Nochi, Zahra Schubart, Karin Boesl, Irmgard Wittayer, Matthias Pelz, Bernhard Leone, Caterina Schilder, Andreas Phillips, Keith G. Vollert, Jan Li, Thomas Schnetter, Erik Wanigasekera, Vishvarani Finnerup, Nanna B. Goetz, Marcus Genser, Bernd Tracey, Irene Truini, Andrea Bloms-Funke, Petra Pogatzki-Zahn, Esther Vela, Jose Miguel Mouraux, André |
| Author_xml | – sequence: 1 givenname: Zahra surname: Nochi fullname: Nochi, Zahra organization: Danish Pain Research Center, Department of Clinical Medicine, Aarhus University – sequence: 2 givenname: Hossein surname: Pia fullname: Pia, Hossein organization: Danish Pain Research Center, Department of Clinical Medicine, Aarhus University – sequence: 3 givenname: Petra surname: Bloms-Funke fullname: Bloms-Funke, Petra organization: Translational Science & Intelligence, Grünenthal GmbH – sequence: 4 givenname: Irmgard surname: Boesl fullname: Boesl, Irmgard organization: Clinical Science Development, Grünenthal GmbH – sequence: 5 givenname: Ombretta surname: Caspani fullname: Caspani, Ombretta organization: Department of Neurophysiology, Mannheim Center for Translational Neurosciences (MCTN), University of Heidelberg – sequence: 6 givenname: Sonya C. surname: Chapman fullname: Chapman, Sonya C. organization: Eli Lilly and Company – sequence: 7 givenname: Francesca surname: Fardo fullname: Fardo, Francesca organization: Danish Pain Research Center, Department of Clinical Medicine, Aarhus University – sequence: 8 givenname: Bernd surname: Genser fullname: Genser, Bernd organization: Mannheim Institute of Public Health, Social & Preventive Medicine, University of Heidelberg – sequence: 9 givenname: Marcus surname: Goetz fullname: Goetz, Marcus organization: MRC Systems GmbH – sequence: 10 givenname: Anna V. surname: Kostenko fullname: Kostenko, Anna V. organization: Department of Neurophysiology, Mannheim Center for Translational Neurosciences (MCTN), University of Heidelberg – sequence: 11 givenname: Caterina surname: Leone fullname: Leone, Caterina organization: Department of Human Neuroscience, Sapienza University – sequence: 12 givenname: Thomas surname: Li fullname: Li, Thomas organization: Teva Branded Pharmaceutical Products R&D – sequence: 13 givenname: André surname: Mouraux fullname: Mouraux, André organization: Institute of Neuroscience (IoNS), UCLouvain – sequence: 14 givenname: Bernhard surname: Pelz fullname: Pelz, Bernhard organization: MRC Systems GmbH – sequence: 15 givenname: Esther surname: Pogatzki-Zahn fullname: Pogatzki-Zahn, Esther organization: Department of Anaesthesiology, Intensive Care and Pain Medicine, University Hospital Münster – sequence: 16 givenname: Andreas surname: Schilder fullname: Schilder, Andreas organization: Department of Neurophysiology, Mannheim Center for Translational Neurosciences (MCTN), University of Heidelberg – sequence: 17 givenname: Erik surname: Schnetter fullname: Schnetter, Erik organization: University Computing Centre, University of Heidelberg – sequence: 18 givenname: Karin surname: Schubart fullname: Schubart, Karin organization: ConsulTech GmbH – sequence: 19 givenname: Alexandre surname: Stouffs fullname: Stouffs, Alexandre organization: Institute of Neuroscience (IoNS), UCLouvain – sequence: 20 givenname: Irene surname: Tracey fullname: Tracey, Irene organization: Wellcome Centre for Integrative Neuroimaging, FMRIB Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital – sequence: 21 givenname: Iñaki F. surname: Troconiz fullname: Troconiz, Iñaki F. organization: Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra – sequence: 22 givenname: Andrea surname: Truini fullname: Truini, Andrea organization: Department of Human Neuroscience, Sapienza University – sequence: 23 givenname: Johannes surname: Van Niel fullname: Van Niel, Johannes organization: Mature Products Development, Grünenthal GmbH – sequence: 24 givenname: Jose Miguel surname: Vela fullname: Vela, Jose Miguel organization: Welab Barcelona – sequence: 25 givenname: Katy surname: Vincent fullname: Vincent, Katy organization: Nuffield Department of Women’s and Reproductive Health (NDWRH), University of Oxford – sequence: 26 givenname: Jan surname: Vollert fullname: Vollert, Jan organization: Pain Research, Department of Surgery and Cancer, Imperial College London – sequence: 27 givenname: Vishvarani surname: Wanigasekera fullname: Wanigasekera, Vishvarani organization: Wellcome Centre for Integrative Neuroimaging, FMRIB Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital – sequence: 28 givenname: Matthias surname: Wittayer fullname: Wittayer, Matthias organization: Department of Neurophysiology, Mannheim Center for Translational Neurosciences (MCTN), University of Heidelberg – sequence: 29 givenname: Hatice surname: Tankisi fullname: Tankisi, Hatice organization: Department of Clinical Medicine, Aarhus University and Department of Clinical Neurophysiology, Aarhus University Hospital – sequence: 30 givenname: Nanna B. orcidid: 0000-0001-5541-0240 surname: Finnerup fullname: Finnerup, Nanna B. email: finnerup@clin.au.dk organization: Danish Pain Research Center, Department of Clinical Medicine, Aarhus University – sequence: 31 givenname: Keith G. surname: Phillips fullname: Phillips, Keith G. organization: Neuroscience Next Generation Therapeutics, Eli Lilly and Company, Lilly Innovation Center – sequence: 32 givenname: Rolf-Detlef surname: Treede fullname: Treede, Rolf-Detlef organization: Department of Neurophysiology, Mannheim Center for Translational Neurosciences (MCTN), University of Heidelberg |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35183242$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9U8tuEzEUHVARfcAPsECW2BSpU_yYh8MCCaICkcpDqKwt23MncXDsYHsiwtfjSVqgXXTl1znnnnNtHxcHzjsoimcEnxPCm1eRMNywElNa4gbztiQPiyPSVnXZUFIf_Dc_LI5jXGJcsQmrHheHrCac0YoePTiffZrR8qs0bioDlO-MH-flt-kVeY1iGrotWgefvPYW9T4giYJ0nV-Z39Cdoc4PykKprHF5tbZSg_Kl9i4Fb-2I0MHH6DcQztBqsMmUGlyCgFIw0iLj0AKkTYstioNagk4RJZ-3NxCTmcsEKC0AQd_vjnyPcgkf5cp0kOsFmEslc_EzlE2hJNdZXHbZqndIGb-S4QeEHW-dU41JNMRo3Bx5FSFsoEMqB4Rg1gsI2ZAbNxH80iZJZaxJW5RGK5lx-vni6uWT4lEvbYSn1-NJ8f39xdX0Y3n55cNs-vay1HWFU6k1z7eSu911PceqkRVQUnVVXtNJA0oyxjinvCNS45oTLZtWykya9A2TRLOTYrbX7bxcinUwOcpWeGnEbsOHuZAhGW1B1BXrFcVUA1EVU81E0r5vKtpyVVGuSdZ6s9daD2oF3XgBOeot0dsnzizE3G8E53XLW5YFTq8Fgv855HaIlYkarJUO_BAFbRhpclzOM_TFHejSD8HlVgnaMsyqupngjHr-v6O_Vm6eZQbwPWD3fAL0YryQZMaHJY0VBIvxB4j9DxC512L3A8SYlt6h3qjfS2J7UsxgN4fwz_Y9rD9AJB6a |
| CitedBy_id | crossref_primary_10_1016_j_cnp_2023_03_003 crossref_primary_10_3390_ijms23158295 |
| Cites_doi | 10.1007/s40268-015-0094-8 10.1097/j.pain.0000000000000454 10.1093/brain/123.12.2542 10.1185/03007995.2010.537589 10.1186/s13063-021-05272-y 10.1002/(sici)1097-4598(199802)21:2<137::aid-mus1>3.0.co;2-c 10.1016/j.pain.2011.02.037 10.1152/jn.00629.2019 10.1523/JNEUROSCI.1222-03.2004 10.2337/dc09-1578 10.1177/0091270009352087 10.1016/j.jpain.2009.01.322 10.1093/brain/awy329 10.1111/j.1528-1167.2012.03725.x 10.1002/cpt.1096 10.2337/dc13-2291 10.1007/s40261-014-0211-4 10.1097/AJP.0b013e318196d2b6 10.1037/1040-3590.7.4.524 10.1016/j.pain.2009.06.020 10.1016/j.clinph.2021.02.397 10.1152/jn.00651.2013 10.1517/13543784.2010.511174 10.1002/sim.3495 10.1097/WCO.0b013e3283304c9d 10.1097/01.ajp.0000210957.39621.b2 10.1159/000339077 10.1002/sim.4780100611 10.1016/j.clinph.2009.12.034 10.1016/S0140-6736(86)90837-8 10.1097/AAP.0b013e3181fa6b7a |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13063-022-06087-1 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) ProQuest Nursing & Allied Health Database ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1745-6215 |
| EndPage | 20 |
| ExternalDocumentID | oai_doaj_org_article_543fb202ce1b43b69a2ff64278b428c1 PMC8857873 35183242 10_1186_s13063_022_06087_1 |
| Genre | Clinical Trial Protocol Journal Article |
| GeographicLocations | United Kingdom--UK Aachen Germany Belgium United States--US Denmark Aarhus Denmark Germany Spain |
| GeographicLocations_xml | – name: Germany – name: United Kingdom--UK – name: Denmark – name: Aarhus Denmark – name: Aachen Germany – name: Spain – name: Belgium – name: United States--US |
| GrantInformation_xml | – fundername: Horizon 2020 Framework Programme grantid: No 777500 funderid: http://dx.doi.org/10.13039/100010661 – fundername: Horizon 2020 Framework Programme grantid: No 777500 – fundername: ; grantid: No 777500 |
| GroupedDBID | --- 0R~ 123 2-G 29Q 2WC 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACUHS ADBBV ADRAZ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHYZX AIAGR ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ O5R O5S OVT PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP WOQ WOW ~8M AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM 3V. 5GY 7XB 8FK AHMBA AZQEC COVID DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS XSB 7X8 5PM |
| ID | FETCH-LOGICAL-c540t-cc8022439ddf80b6a4e214d49dd296eba3338828d1ac0581ca67aac809f63a1c3 |
| IEDL.DBID | C6C |
| ISSN | 1745-6215 |
| IngestDate | Wed Aug 27 01:29:29 EDT 2025 Thu Aug 21 13:52:37 EDT 2025 Fri Sep 05 05:45:29 EDT 2025 Fri Jul 25 20:59:00 EDT 2025 Thu Apr 03 07:08:20 EDT 2025 Thu Apr 24 23:09:43 EDT 2025 Tue Jul 01 04:01:03 EDT 2025 Sat Sep 06 07:26:42 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Threshold tracking PK/PD RCT Pain Analgesics Biomarkers Healthy subjects Ectopic impulse generation Nerve excitability testing Hyperalgesia |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c540t-cc8022439ddf80b6a4e214d49dd296eba3338828d1ac0581ca67aac809f63a1c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| ORCID | 0000-0001-5541-0240 |
| OpenAccessLink | https://doi.org/10.1186/s13063-022-06087-1 |
| PMID | 35183242 |
| PQID | 2730345690 |
| PQPubID | 44365 |
| PageCount | 20 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_543fb202ce1b43b69a2ff64278b428c1 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8857873 proquest_miscellaneous_2631622488 proquest_journals_2730345690 pubmed_primary_35183242 crossref_citationtrail_10_1186_s13063_022_06087_1 crossref_primary_10_1186_s13063_022_06087_1 springer_journals_10_1186_s13063_022_06087_1 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-02-19 |
| PublicationDateYYYYMMDD | 2022-02-19 |
| PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-19 day: 19 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Current controlled trials in cardiovascular medicine |
| PublicationTitleAbbrev | Trials |
| PublicationTitleAlternate | Trials |
| PublicationYear | 2022 |
| Publisher | BioMed Central BMC |
| Publisher_xml | – name: BioMed Central – name: BMC |
| References | C Krarup (6087_CR6) 2009; 22 MJL Sullivan (6087_CR30) 1995; 7 JP Wymer (6087_CR14) 2009; 25 RL Rauck (6087_CR13) 2007; 23 EN van den Broeke (6087_CR9) 2014; 111 R Schwarzer (6087_CR29) 1995 A Mouraux (6087_CR2) 2021; 22 DB Pfau (6087_CR25) 2011; 152 MC Kiernan (6087_CR4) 2000; 123 S Isose (6087_CR27) 2010; 121 S Schwartz (6087_CR23) 2011; 27 W Cawello (6087_CR17) 2013; 54 B Namer (6087_CR16) 2019; 39 W Cawello (6087_CR18) 2012; 90 A Filipe (6087_CR21) 2015; 15 AI Vinik (6087_CR24) 2014; 37 J Tigerholm (6087_CR7) 2020; 124 A Buvanendran (6087_CR22) 2010; 35 R Ruscheweyh (6087_CR31) 2009; 146 ASC Rice (6087_CR1) 2016; 157 HN Bockbrader (6087_CR19) 2010; 50 F Bretz (6087_CR33) 2009; 28 6087_CR32 ML Chew (6087_CR20) 2014; 34 J Martin Bland (6087_CR34) 1986; 327 AG Kristensen (6087_CR5) 2021; 132 6087_CR3 T Klein (6087_CR8) 2004; 24 S Senn (6087_CR28) 1991; 10 MO Kovalchuk (6087_CR26) 2018; 104 G McCleane (6087_CR10) 2010; 19 D Ziegler (6087_CR11) 2010; 33 A Shaibani (6087_CR12) 2009; 10 BTA de Greef (6087_CR15) 2019; 142 |
| References_xml | – start-page: 35 volume-title: Measures in health psychology: a user’s portfolio causal and control beliefs year: 1995 ident: 6087_CR29 – volume: 15 start-page: 195 issue: 2 year: 2015 ident: 6087_CR21 publication-title: Drugs R D. doi: 10.1007/s40268-015-0094-8 – volume: 157 start-page: 791 issue: 4 year: 2016 ident: 6087_CR1 publication-title: Pain. doi: 10.1097/j.pain.0000000000000454 – volume: 123 start-page: 2542 issue: Pt 12 year: 2000 ident: 6087_CR4 publication-title: Brain doi: 10.1093/brain/123.12.2542 – volume: 27 start-page: 151 issue: 1 year: 2011 ident: 6087_CR23 publication-title: Curr Med Res Opin doi: 10.1185/03007995.2010.537589 – volume: 22 start-page: 404 issue: 1 year: 2021 ident: 6087_CR2 publication-title: Trials. doi: 10.1186/s13063-021-05272-y – ident: 6087_CR3 doi: 10.1002/(sici)1097-4598(199802)21:2<137::aid-mus1>3.0.co;2-c – volume: 152 start-page: 1532 issue: 7 year: 2011 ident: 6087_CR25 publication-title: Pain. doi: 10.1016/j.pain.2011.02.037 – volume: 124 start-page: 883 issue: 3 year: 2020 ident: 6087_CR7 publication-title: J Neurophysiol doi: 10.1152/jn.00629.2019 – volume: 24 start-page: 964 issue: 4 year: 2004 ident: 6087_CR8 publication-title: J Neurosci. doi: 10.1523/JNEUROSCI.1222-03.2004 – volume: 33 start-page: 839 issue: 4 year: 2010 ident: 6087_CR11 publication-title: Diabetes Care. doi: 10.2337/dc09-1578 – volume: 50 start-page: 941 issue: 8 year: 2010 ident: 6087_CR19 publication-title: J Clin Pharmacol doi: 10.1177/0091270009352087 – volume: 10 start-page: 818 issue: 8 year: 2009 ident: 6087_CR12 publication-title: J Pain. doi: 10.1016/j.jpain.2009.01.322 – volume: 142 start-page: 263 issue: 2 year: 2019 ident: 6087_CR15 publication-title: Brain. doi: 10.1093/brain/awy329 – volume: 39 start-page: 401 year: 2019 ident: 6087_CR16 publication-title: EBioMedicine. doi: 10.1093/brain/awy329 – volume: 54 start-page: 81 issue: 1 year: 2013 ident: 6087_CR17 publication-title: Epilepsia. doi: 10.1111/j.1528-1167.2012.03725.x – volume: 104 start-page: 1136 issue: 6 year: 2018 ident: 6087_CR26 publication-title: Clin Pharmacol Ther. doi: 10.1002/cpt.1096 – volume: 37 start-page: 2302 issue: 8 year: 2014 ident: 6087_CR24 publication-title: Diabetes Care. doi: 10.2337/dc13-2291 – volume: 34 start-page: 617 issue: 9 year: 2014 ident: 6087_CR20 publication-title: Clin Drug Investig. doi: 10.1007/s40261-014-0211-4 – volume: 25 start-page: 376 issue: 5 year: 2009 ident: 6087_CR14 publication-title: Clin J Pain. doi: 10.1097/AJP.0b013e318196d2b6 – volume: 7 start-page: 9 issue: 4 year: 1995 ident: 6087_CR30 publication-title: Psychol Assess doi: 10.1037/1040-3590.7.4.524 – ident: 6087_CR32 – volume: 146 start-page: 65 issue: 1 year: 2009 ident: 6087_CR31 publication-title: Pain doi: 10.1016/j.pain.2009.06.020 – volume: 132 start-page: 1407 issue: 7 year: 2021 ident: 6087_CR5 publication-title: Clin Neurophysiol. doi: 10.1016/j.clinph.2021.02.397 – volume: 111 start-page: 1564 issue: 8 year: 2014 ident: 6087_CR9 publication-title: J Neurophysiol doi: 10.1152/jn.00651.2013 – volume: 19 start-page: 1129 issue: 9 year: 2010 ident: 6087_CR10 publication-title: Expert Opinion on Investigational Drugs. doi: 10.1517/13543784.2010.511174 – volume: 28 start-page: 586 issue: 4 year: 2009 ident: 6087_CR33 publication-title: Statist Med. doi: 10.1002/sim.3495 – volume: 22 start-page: 460 issue: 5 year: 2009 ident: 6087_CR6 publication-title: Curr Opin Neurol. doi: 10.1097/WCO.0b013e3283304c9d – volume: 23 start-page: 150 issue: 2 year: 2007 ident: 6087_CR13 publication-title: Clin J Pain. doi: 10.1097/01.ajp.0000210957.39621.b2 – volume: 90 start-page: 40 issue: 1–2 year: 2012 ident: 6087_CR18 publication-title: Pharmacology. doi: 10.1159/000339077 – volume: 10 start-page: 906 issue: 6 year: 1991 ident: 6087_CR28 publication-title: Stat Med. doi: 10.1002/sim.4780100611 – volume: 121 start-page: 719 issue: 5 year: 2010 ident: 6087_CR27 publication-title: Clin Neurophysiol doi: 10.1016/j.clinph.2009.12.034 – volume: 327 start-page: 307 issue: 8476 year: 1986 ident: 6087_CR34 publication-title: Lancet. doi: 10.1016/S0140-6736(86)90837-8 – volume: 35 start-page: 535 issue: 6 year: 2010 ident: 6087_CR22 publication-title: Pain Med doi: 10.1097/AAP.0b013e3181fa6b7a |
| SSID | ssj0043934 ssj0017864 |
| Score | 2.3007927 |
| Snippet | Background
Few new drugs have been developed for chronic pain. Drug development is challenged by uncertainty about whether the drug engages the human target... Few new drugs have been developed for chronic pain. Drug development is challenged by uncertainty about whether the drug engages the human target sufficiently... BackgroundFew new drugs have been developed for chronic pain. Drug development is challenged by uncertainty about whether the drug engages the human target... Abstract Background Few new drugs have been developed for chronic pain. Drug development is challenged by uncertainty about whether the drug engages the human... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 163 |
| SubjectTerms | Analgesics Authorship Biomarkers Biomedicine Brain research Chronic pain Clinical outcomes Clinical trials Consortia Double-Blind Method Double-blind studies Drug development Drug dosages Health care Health Sciences Healthy Volunteers Humans Hyperalgesia Innovations Lacosamide Medicine Medicine & Public Health Multicenter Studies as Topic Nerve excitability testing Neurophysiology Neurosciences Objectives Pain Peripheral Nerves Pharmaceuticals PK/PD Pregabalin Randomized Controlled Trials as Topic Research centers Spinal cord Statistics for Life Sciences Study Protocol Tapentadol Threshold tracking |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEDaoB8QF8SZQ0CBxALGmseN4HW60alUhtUKolXqL7NiGlbbxajcrUX49YydZWJ4XboljK-PJeB7xzGdCXjDHlXOlp9LpnIqp4VRPjaAS7QnjvLK5jzu6J6fy-Fy8vygvfjjqK-aE9fDAPeP2SlF4gxF645gRhZGV5t7LeECEQc-5SYFPXuVjMNXrYLSyhRhLZJTcW6GmTvuVnOYyx2XFtsxQQuv_nYv5a6bkT9ulyQod3Sa3BvcR3vVk3yHXXXuX3DgZNsjvXXuDuojTDxjux8Iiuj8L8Zp-PDhjbyFByUJEZgj4-QHdVdCAtsqGy9lXZydgw9rMHTXoeuJdStcygQ7Z7PPYI80mZn1OIKUi0kiyW0I6_ANmLfR1lVewWpv4h2cFXcDmEcvDAfqbMOSQQPCArwgrfTmzDt-3dJ-0wbignQASBZ1exMR2i6SGFiJOQEwlWqZxC5wVLPoiB2QUBBP_LjsLBieIiyqBJcyhjY3gvjSzrscjv4IukoIjXp4enr26T86PDs8OjulwJARt0LXsaNPE0mD8vNZ6lRupheNMWIH3vJLO6AJDbgwiLdNNXirWaDnVGgdVXhaaNcUDstOG1j0ioCxXyhhdmrwQmpnKa-W58ab0jXBWZYSNElI3A156PLZjXqe4Scm6l6oaCaqTVNUsI683YxY9Wshfe-9Hwdv0jEjfqQHlvx7kv_6X_GdkdxTbelA_qxp9UpxUKas8I883j1FxxN0g3bqwxj6yYBJ5qXCmD3sp31BSlFHTC56R6Zb8b5G6_aSdfU7g5EpFG1BkZDKulO9k_ZkVj_8HK56QmzwtcU5ZtUt2uuXaPUWXsTPPknb4BpuMbPg priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1db9Mw0MCQEC-IbwoDHRIPIGoWO4nr8ILYtGlC2oRQJ_UtsmNnVOri0qYS49dz56SdysfeEsdOzs59-s53jL0RXmrv85orbxKejazkZmQzrlCeCCkLl9Tk0T05Vcdn2ZdJPuk33JZ9WOWaJ0ZG7UJFe-R7KGaTFKV9kXya_-BUNYq8q30JjVvstkBNhEo3jCYbg0uMtMrWB2W02lsiv45eS8kTlSBxiS1hFHP2_0vR_Dte8g-naZRFR_fZvV6JhM_dX3_AbvrmIbtz0rvJH934gBxJ8q9o9NPxIr4_DXTNvx2MxUeICWWB8jMERAJApRUMoMRy4WL6y7shuLCyM88tKqB4F4O2bOB9TPuMesTZUOznEGJAIieQ_QJiCRCYNtCdrryE5crSPs8S2oDN64weHlDrhD6SBEIN-ImwNBdT5_F7C39uLFoHzRAQKGjNnMLbHYIaGqBsARRQtIjj5jgrmHdHHXChIFjaY_YOLE4QSSumTJhBQ43gf1bTtstKfgktgYIj3p4ejt89ZmdHh-ODY94XhuAVKpgtryo6IIyqlHO1TqwymZcicxney0J5a1I0vNGUdMJUSa5FZdTIGBxU1Co1okqfsJ0mNP4ZA-2k1taa3CJ2GWGL2uha2trmdZV5pwdMrDGkrPqs6VS8Y1ZG60mrssOqEgEqI1aVYsDeb8bMu5wh1_beJ8Tb9KR837EhLM7Lnn2UeZbWViay8sJmqVWFkXWtqEyKRfuxwpfsrtG27JnQsrwimQF7vXmM7IN8QqbxYYV9VCoUrqXGmT7tsHwDSZoTv8_kgI228H8L1O0nzfR7TFGuNUmCdMCGa0q5Auv_S_H8-lm8YHdlJF7JRbHLdtrFyr9ElbC1ryLd_wZixmTJ priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3va9QwNI4J4hfxt6dTnuAHxcts0jSXCiJubAxhQ2SDfStJk87CrTnverDzr_clbU9Op-C3a5pcX9L3s-8XIa-Y48q5rKLS6YSKieFUT4ygEuUJ4zy3SRU8uscn8uhMfD7PzrfI0O6oP8DFtaZd6Cd1Np_uXn1ffUSC_xAJXsl3C-TD0RvJaSITJBq0hm5Gf1EI5RNrrwLK3lQMiTPXrtsQTrGG_3WK55_xk785UaNsOrxL7vRKJXzqsOAe2XLNfXLruHebP7ixixyK0y-6bkK6Ed2rffhNv-6fsvcQC8xCqNfgESkAlVjQgBLM-sv6h7NjsH5ppo4aVEjxKgZxGU_7GPdpmBF3E2JBxxADFGkA2c0htgSBuoEu23IFi6UJ330W0HocHip8OEAtFPrIEvAV4CP8Ql_W1uHz5u5CG7QWmjEgUNDqWQh3twiqbyBUDwgBRvO4boa7glmX-oAHBd6Eb87OgsENIqnFEgpTaMIguKuybrsq5StoAyi44vXJwembh-Ts8OB0_4j2jSJoiQpnS8syJAzj67W2UomRWjjOhBV4zXPpjE7REEfT0jJdJplipZYTrXFRXslUszJ9RLYb37gnBJTlShmjM5OkQjOTV1pV3FQmq0rhrBoRNmBIUfZV1EMzj2kRrSkliw6rCgSoiFhVsBF5u14z62qI_HP2XkC89cxQ_zsO-PlF0bOTIhNpZXjCS8eMSI3MNa8qGdqmGLQnS_yTnQFti4GmCtRUcVOZzJMRebm-jewk-Ih04_wS58iUSTxLhTt93GH5GpI0C_xf8BGZbOD_Bqibd5r6WyxZrlSQDOmIjAdK-QXW34_i6f9Nf0Zu80jMnLJ8h2y386V7jipja15EPvAThb9sJQ priority: 102 providerName: Scholars Portal |
| Title | IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET) |
| URI | https://link.springer.com/article/10.1186/s13063-022-06087-1 https://www.ncbi.nlm.nih.gov/pubmed/35183242 https://www.proquest.com/docview/2730345690 https://www.proquest.com/docview/2631622488 https://pubmed.ncbi.nlm.nih.gov/PMC8857873 https://doaj.org/article/543fb202ce1b43b69a2ff64278b428c1 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwEDewSYgXxDeFUR0SDyDqETuO6_DWTR3TpFbT6KS-RXbsQKUuqdpUYvz1nJ20UBhIvLiNYydn53y-851_JuQNc1w5lxRUOh1R0Tec6r4RVOJ8wjhPbVR4j-5oLE8vxdk0mbYwOX4vzK_-e6bkhxXK2OBp5DSSEQ4ItHT2E5_pHbPyeCN1cV6NxWZTzI31diaegM9_k1L5Z2zkbw7SMO-cPCD3W4URBs0Xfkhuu_IRuTtqXeKPbx2i9OH0HA18v5WIHs0q_59eHE_YRwjgseCxGCr84IAKKmjA2clWV7PvzvbAVmszd9SgsolXIUDLVLSNX5_7EqE1Ps6zByH4kHqS3RLCcR8wK6HZSXkNq7XxazorqCvM3qB3OEANE9qoEagKwFdUK301sw7ft3RftEFLoOwBEgW1XvhQdoukViV4ZAAfPLQM9RbYKlg02xqwo6Ayfj3ZWTDYQBxGAR5hDqXPBPctn9UNAvk11J4UrPF2PJy8e0IuT4aT41PaHgJBc1Qma5rnfjMwfl5rCxUZqYXjTFiB1zyVzugYjWw0Gy3TeZQolmvZ1xorpYWMNcvjp2SvrEr3nICyXCljdGKiWGhm0kKrgpvCJEUunFUdwjYckuUtQro_qGOeBUtJyazhqgwJygJXZaxD3m_rLBp8kH-WPvKMty3psb1DBrJ81oqKLBFxYXjEc8eMiI1MNS8K6Y9EMWgr5viQgw3bZq3AWWWohWKjEplGHfJ6extFhff_6NJVaywjYyaxLxW29FnD5VtK4sTLdsE7pL_D_zuk7t4pZ18DHLlSXurHHdLbjJSfZP29K178X_GX5B4Pg5lTlh6QvXq5dq9QHaxNl9zpT_tdsj8YnH0-w9-j4fj8ohukQzcssWD6acowHQmF6SUf_AB9JmVT |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1MAmAS-IO4UBBwkkEDWLncR1kCbExqaNbdU0ddLegh07o1KXlDYVjI_j2zh2kk7lsre9JY6dHDvH5-JzI-Qls1xaG-dUWBXQqKc5VT0dUYH8hHGemCB3Ft39vtg-ij4fx8dXya82Fsa5VbY00RNqU2bujHwV2WwQIrdPgg_jb9RVjXLW1baEhmpKK5g1n2KsCezYtWffUYWbru18wv_9ivOtzcHGNm2qDNAMpZWKZpmLNkW-bEwuAy1UZDmLTIT3PBFWqxC1ONRLDFNZEEuWKdFTCgcluQgVy0J87zWyHLkDlCWyvL7ZPzic2zF6UkRtqI4Uq1PkGN5uymkgAtzebIEd-qoB_xJ1__bY_MNs67nh1m1yqxFj4WONd3fIVVvcJdf3G0P9vSvvkCZyeqCGhQtwouvD0l3Tw40Bew8-pS24DBEloiGg2AwKkGea8nT405oumHKmR5ZqFIHxzruN6ZI2XvUj18PPxnmfdsG7RFIHsp2AL0ICwwLq-M4zmM60O2maQlVic5tTxALKvdD4skCZA36inKrTobH4vYk9URr1k6ILCBRUauwc7A2CWhbg8hU4l6aJHzfGWcG4DrbAhYJSu1Nua0DjBHFz-6QNIyhcI9gf2bCq86KfQeVAwRGv-5uDN_fJ0aUgzQOyVJSFfURAGi6l1irWiN-K6SRXMuc613GeRdbIDmEthqRZk7fdlQ8ZpV5_kyKtsSpFgFKPVSnrkLfzMeM6a8mFvdcd4s17uozjvqGcnKQNAUvjKMw1D3hmmY5CLRLF81y4Qi0aNdgMX7LSom3akMFper5pO-TF_DESMGeVUoUtZ9hHhEzgWkqc6cMay-eQhLHjOBHvkN4C_i-AuvikGH71SdKldLwo7JBuu1POwfr_Ujy-eBbPyY3twf5eurfT331CbnK_kTllyQpZqiYz-xQF1Eo_a6gAkC-XTXh-A-lNqEs |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3rb9MwEDdjSBNfEG8KAw4JJBA1i53UcZAQYi9tjE0T6qR9C3bijEhdXNpUMP40_jrOTtKpPPZt35rETs7uz_fwne8Iec4Ml8YMCiqMCmgUa05VrCMqUJ4wzpM8KJxHd_9A7BxFH48Hx0vkV3cWxoVVdjzRM-rcZm6PfA3FbBCitE-CtaINizjc3H4__kZdBSnnae3KaTQQ2TNn39F8m77b3cT_-gXn21vDjR3aVhigGWoqNc0yd9IUZXKeFzLQQkWGsyiP8JonwmgVogWHNknOVBYMJMuUiJXCTkkhQsWyEN97lVyLwyhyZSPi47mxx2Ipou6QjhRrU5QV3mPKaSACXNhsQRD6egH_UnL_jtX8w2Hr5eD2TXKjVWDhQ4O4W2TJVLfJyn7ror9z5Q1yQ04PVVm5o010vbTuN_28MWRvwSezBZcbwiIAARVmUIDSMren5U-T9yG3Mz0yVKPyi1c-YExb2sbTj1wLPxoXd9oHHwxJHclmAr78CJQVNCc7z2A6026PaQq1xdtdNhEDqPFCG8UCtgD8hJ2q0zI3-L2JOVEaLZOqD0gU1GrsQutzJNVW4DIVuGCmie83xlHBuDlmgRMFVrv9bZODxgHisvbpGkZQuZtgfmRl3WREP4PakYI9Xh5sDV_dJUeXApl7ZLmylXlAQOZcSq3VQCOyFdNJoWTBdaEHRRaZXPYI6xCSZm3Gdlc4ZJR6y02KtEFVigSlHlUp65HX8z7jJl_Jha3XHfDmLV2ucX_DTk7SlnWlgygsNA94ZpiOQi0SxYtCuBItGm3XDF-y2sE2bRngND1frj3ybP4YWZfzR6nK2Bm2ESETOJcSR3q_QfmcknDgZE3EeyRewP8CqYtPqvKrT48upZNCYY_0u5VyTtb_p-LhxaN4SlaQ3aSfdg_2HpHr3K9jTlmySpbrycw8Rs201k88CwDy5bJ5zm9qN6Xn |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=IMI2-PainCare-BioPain-RCT1%3A+study+protocol+for+a+randomized%2C+double-blind%2C+placebo-controlled%2C+crossover%2C+multi-center+trial+in+healthy+subjects+to+investigate+the+effects+of+lacosamide%2C+pregabalin%2C+and+tapentadol+on+biomarkers+of+pain+processing+observed+by+peripheral+nerve+excitability+testing+%28NET%29&rft.jtitle=Trials&rft.au=Nochi%2C+Zahra&rft.au=Pia%2C+Hossein&rft.au=Bloms-Funke%2C+Petra&rft.au=Boesl%2C+Irmgard&rft.date=2022-02-19&rft.pub=BioMed+Central&rft.eissn=1745-6215&rft.volume=23&rft.issue=1&rft_id=info:doi/10.1186%2Fs13063-022-06087-1&rft.externalDocID=10_1186_s13063_022_06087_1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |